title: A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
abstract: In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.
authors.affiliation: HMDS, St James's Institute of Oncology, Leeds, UK.
authors.forename: A C
authors.initials: AC
authors.lastname: Rawstron
authors.affiliation: IRCCS San Raffaele Scientific Institute, Milano, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Fazi
authors.affiliation: IRCCS San Raffaele Scientific Institute, Milano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Agathangelidis
authors.affiliation: Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: N
authors.initials: N
authors.lastname: Villamor
authors.affiliation: Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
authors.forename: R
authors.initials: R
authors.lastname: Letestu
authors.affiliation: Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Nomdedeu
authors.affiliation: Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Palacio
authors.affiliation: Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
authors.forename: O
authors.initials: O
authors.lastname: Stehlikova
authors.affiliation: University Hospital, Cologne, Germany.
authors.forename: K-A
authors.initials: KA
authors.lastname: Kreuzer
authors.affiliation: St James Hospital, Dublin, Ireland.
authors.forename: S
authors.initials: S
authors.lastname: Liptrot
authors.affiliation: St James Hospital, Dublin, Ireland.
authors.forename: D
authors.initials: D
authors.lastname: O'Brien
authors.affiliation: HMDS, St James's Institute of Oncology, Leeds, UK.
authors.forename: R M
authors.initials: RM
authors.lastname: de Tute
authors.affiliation: Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague, Czech Republic.
authors.forename: I
authors.initials: I
authors.lastname: Marinov
authors.affiliation: University Hospital Geneva, Geneva, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Hauwel
authors.affiliation: General University Hospital, Prague, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Spacek
authors.affiliation: Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Dobber
authors.affiliation: Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.
authors.forename: A P
authors.initials: AP
authors.lastname: Kater
authors.affiliation: Peter MacCallum Cancer Centre, Melbourne, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Gambell
authors.affiliation: Hematology and Flow Cytometry, Laverty Pathology, Sydney, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Soosapilla
authors.affiliation: Ohio State University Medical Center, Columbus, OH, USA.
authors.forename: G
authors.initials: G
authors.lastname: Lozanski
authors.affiliation: 3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.|Experimental and Clinical Cell Therapy Institute, Spinal Cord and Tissue Regeneration Center, Paracelsus Medical University, Salzburg, Austria.
authors.forename: G
authors.initials: G
authors.lastname: Brachtl
authors.affiliation: Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
authors.forename: K
authors.initials: K
authors.lastname: Lin
authors.affiliation: Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: J
authors.initials: J
authors.lastname: Boysen
authors.affiliation: Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: C
authors.initials: C
authors.lastname: Hanson
authors.affiliation: MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Jorgensen
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: M
authors.initials: M
authors.lastname: Stetler-Stevenson
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: C
authors.initials: C
authors.lastname: Yuan
authors.affiliation: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
authors.forename: H E
authors.initials: HE
authors.lastname: Broome
authors.affiliation: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
authors.forename: L
authors.initials: L
authors.lastname: Rassenti
authors.affiliation: Un1iversity of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: F
authors.initials: F
authors.lastname: Craig
authors.affiliation: Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Delgado
authors.affiliation: Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Moreno
authors.affiliation: Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Bosch
authors.affiliation: 3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Egle
authors.affiliation: Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Doubek
authors.affiliation: Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
authors.forename: S
authors.initials: S
authors.lastname: Pospisilova
authors.affiliation: Department of Haematology, Royal North Shore Hospital, Sydney, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Mulligan
authors.affiliation: Peter MacCallum Cancer Centre, Melbourne, Australia.
authors.forename: D
authors.initials: D
authors.lastname: Westerman
authors.affiliation: Adaptive Biotechnologies, Seattle, WA, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Sanders
authors.affiliation: Adaptive Biotechnologies, Seattle, WA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Emerson
authors.affiliation: Adaptive Biotechnologies, Seattle, WA, USA.
authors.forename: H S
authors.initials: HS
authors.lastname: Robins
authors.affiliation: Adaptive Biotechnologies, Seattle, WA, USA.
authors.forename: I
authors.initials: I
authors.lastname: Kirsch
authors.affiliation: Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: T
authors.initials: T
authors.lastname: Shanafelt
authors.affiliation: Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
authors.forename: A
authors.initials: A
authors.lastname: Pettitt
authors.affiliation: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
authors.forename: T J
authors.initials: TJ
authors.lastname: Kipps
authors.affiliation: MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: W G
authors.initials: WG
authors.lastname: Wierda
authors.affiliation: Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
authors.forename: F
authors.initials: F
authors.lastname: Cymbalista
authors.affiliation: University Hospital, Cologne, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Hallek
authors.affiliation: Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
authors.forename: P
authors.initials: P
authors.lastname: Hillmen
authors.affiliation: Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Montserrat
authors.affiliation: IRCCS San Raffaele Scientific Institute, Milano, Italy.|Università Vita-Salute San Raffaele, Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Ghia
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000378:metabolism*; D003131:Combined Modality Therapy; D005060:Europe; D005260:Female; D005434:Flow Cytometry / Q000592:standards*; D005500:Follow-Up Studies; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology / Q000628:therapy*; D008297:Male; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D055815:Young Adult
chemical_list: D015703:Antigens, CD